PADI4 and non-small cell lung carcinoma: In summary, a streamlined approach of in silico and in vitro experiments allowed us to select, from 38 different epigenetic targets, the two most promising candidates for NSCLC drug development: PADI4 (GSK 484) and KDM6B (GSK-J4).